These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10701698)

  • 1. Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate.
    Kozutsumi D; Kawashima A; Sugimoto T; Kotohda Y; Fujimori S; Takami M; Kohno T; Oikawa T; Sugino E; Choshi T; Hibino S
    Biopharm Drug Dispos; 1999 Sep; 20(6):277-84. PubMed ID: 10701698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic activity of a novel synthetic agent, 9alpha-fluoromedroxyprogesterone acetate.
    Yamaji T; Tsuboi H; Murata N; Uchida M; Kohno T; Sugino E; Hibino S; Shimamura M; Oikawa T
    Cancer Lett; 1999 Oct; 145(1-2):107-14. PubMed ID: 10530777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and anti-tumor activity of a fluorinated analog of medroxyprogesterone acetate (MPA), 9alpha-fluoromedroxyprogesterone acetate (FMPA).
    Murata N; Fujimori S; Ichihara Y; Sato Y; Yamaji T; Tsuboi H; Uchida M; Suzuki H; Yamada M; Oikawa T; Nemoto H; Nobuhiro J; Choshi T; Hibino S
    Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1567-70. PubMed ID: 17077554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition by 9alpha-fluoromedoroxyprogesterone acetate (FMPA) against mammary carcinoma induced by dimethylbenz[a]anthracene in rats and angiogenesis in the rabbit cornea - comparison with medroxyprogesterone acetate (MPA).
    Uchida M; Tsuboi H; Yamaji T; Murata N; Kohno T; Sugino E; Hibino S; Shimamura M; Oikawa T
    Cancer Lett; 2000 Jun; 154(1):63-9. PubMed ID: 10799740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of laser-induced choroidal neovascularization by subconjunctival injection of 9alpha-fluoromedroxyprogesterone acetate (FMPA), an anti-angiogenic agent, in rats.
    Murata N; Yamaji T; Uchida M; Tsuboi H; Suzuki H; Yamada M; Oikawa T; Nobuhiro J; Choshi T; Hibino S
    Biol Pharm Bull; 2006 Dec; 29(12):2410-4. PubMed ID: 17142973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of a new potent anti-angiogenic agent, 17 alpha-acetoxy-9 alpha-fluoro-6 alpha-methylprogesterone (9 alpha-fluoromedroxyprogesterone acetate [FMPA]).
    Sugino E; Fujimori S; Hibino S; Choshi T; Ichihara Y; Sato Y; Yamaji T; Tsuboi H; Murata N; Uchida M; Shimamura M; Oikawa T
    Chem Pharm Bull (Tokyo); 1997 Feb; 45(2):421-3. PubMed ID: 9118456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
    Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
    Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.
    Etienne MC; Milano G; René N; Benedetti MS; Efthymiopoulos C; Vo Van ML; Hurteloup P; Montcuquet P; Frenay M; Namer M
    J Pharm Sci; 1991 Dec; 80(12):1130-2. PubMed ID: 1839998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer.
    Utaaker E; Lundgren S; Kvinnsland S; Aakvaag A
    J Steroid Biochem; 1988 Oct; 31(4A):437-41. PubMed ID: 2971841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
    Laatikainen T; Nieminen U; Adlercreutz H
    Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
    Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
    J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunoassays of ethinyl-norgestrienone (R-2323) and medroxyprogesterone acetate (MPA) and their clinical applicability.
    Frick J; Bartsch G; Jakse G
    Urol Res; 1977; 5(2):55-9. PubMed ID: 69351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro metabolism of progestins. III. The metabolic clearance rate of medroxyprogesterone acetate in monkeys.
    Musto NA; Nahrwold D; Miljković M; Bardin CW
    Steroids; 1977 Mar; 29(3):399-406. PubMed ID: 404731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of medroxyprogesterone acetate (MPA), estradiol and progesterone in the rhesus monkey after intramuscular adminstration of Depo-Provera.
    Mora G; Johansson ED
    Contraception; 1976 Sep; 14(3):343-50. PubMed ID: 824097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
    Rahimy MH; Ryan KK
    Contraception; 1999 Oct; 60(4):189-200. PubMed ID: 10640165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
    de Greef WJ; Dullaart J; Zeilmaker GH
    J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses.
    Wikström A; Green B; Johansson ED
    Acta Obstet Gynecol Scand; 1984; 63(2):163-8. PubMed ID: 6233840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
    Stockdale AD; Chapman D; Mould GP; Rostom AY
    Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.